Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
196.25
+3.38 (+1.75%)
Official Closing Price
Updated: 7:00 PM EST, Feb 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
February 18, 2025
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.
Via
StockStory
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
February 18, 2025
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.
Via
Benzinga
Topics
Government
Exposures
Political
How Is The Market Feeling About AbbVie?
February 17, 2025
Via
Benzinga
Is AbbVie Stock a Buy Now?
February 15, 2025
Via
The Motley Fool
Looking At AbbVie's Recent Unusual Options Activity
February 03, 2025
Via
Benzinga
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
February 12, 2025
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers.
Via
Benzinga
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
February 12, 2025
From
Xilio Therapeutics, Inc.; AbbVie Inc.
Via
GlobeNewswire
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
February 11, 2025
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.
Via
StockStory
Healthcare And Biotech Playbook As Disruption Gathers Force
February 10, 2025
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
These Stocks Missed on Earnings, But Will Rebound Next Quarter
February 10, 2025
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year
Via
MarketBeat
Gilead Sciences (GILD) Q4 Earnings: What To Expect
February 10, 2025
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect.
Via
StockStory
3 Fabulous Dividend Stocks to Buy in February
February 09, 2025
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
February 09, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
Via
StockStory
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
February 09, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.
Via
StockStory
3 Dividend Stocks to Double Up on Right Now
February 09, 2025
Via
The Motley Fool
These 2 Dividend Stocks Are Absolute Bargains Right Now
February 08, 2025
Via
The Motley Fool
3 Top AI-Powered Biotech Stocks to Buy in February
February 06, 2025
Via
The Motley Fool
Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase
February 05, 2025
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.” He added, “I can't believe the stock dropped so much.”
Via
Benzinga
Exploring the top movers within the S&P500 index during today's session.
February 03, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.
Via
Chartmill
Can Biotech Stocks Survive The Precarious Macro?
February 03, 2025
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.
Via
Talk Markets
Topics
Stocks / Equities
World Trade
Exposures
Tariff
Top S&P500 movers in Monday's session
February 03, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Via
Chartmill
Nike To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
February 03, 2025
Via
Benzinga
What You Missed On Friday
February 02, 2025
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Topics
Stocks / Equities
U.S. Equity Rally Reverses As White House Confirms Imminent Tariffs, Shifting Focus To Fed Policy
February 02, 2025
Under the surface, markets remain preoccupied with the potential impact of tariffs, shifting inflation expectations, and the Federal Reserve’s policy trajectory.
Via
Talk Markets
Topics
Commodities
Economy
Futures
Exposures
Interest Rates
Tariff
Small- To Mid-Cap Biotech Trades Poised For Gains
February 01, 2025
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.
February 01, 2025
Via
The Motley Fool
What's going on in today's session: S&P500 movers
January 31, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via
Chartmill
AbbVie (NYSE:ABBV) Posts Better-Than-Expected Sales In Q4, Stock Soars
January 31, 2025
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share...
Via
StockStory
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
January 31, 2025
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.
Via
Benzinga
AbbVie (ABBV) Q4 2024 Earnings Call Transcript
January 31, 2025
ABBV earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.